426 related articles for article (PubMed ID: 33946803)
1. Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.
Wallsh JO; Gallemore RP
Cells; 2021 Apr; 10(5):. PubMed ID: 33946803
[TBL] [Abstract][Full Text] [Related]
2. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
3. Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
Behar-Cohen F; Dernigoghossian M; Andrieu-Soler C; Levy R; Cohen R; Zhao M
Drug Discov Today; 2019 Aug; 24(8):1436-1439. PubMed ID: 31173913
[TBL] [Abstract][Full Text] [Related]
4. [Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
Nakamura S; Hara H
Yakugaku Zasshi; 2021; 141(12):1307-1317. PubMed ID: 34853203
[TBL] [Abstract][Full Text] [Related]
5. [Role of VEGF in diseases of the retina].
Barquet LA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
7. Monitoring ocular drug therapy by analysis of aqueous samples.
Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
[TBL] [Abstract][Full Text] [Related]
8. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
Freund KB; Korobelnik JF; Devenyi R; Framme C; Galic J; Herbert E; Hoerauf H; Lanzetta P; Michels S; Mitchell P; Monés J; Regillo C; Tadayoni R; Talks J; Wolf S
Retina; 2015 Aug; 35(8):1489-506. PubMed ID: 26076215
[TBL] [Abstract][Full Text] [Related]
9. A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.
Cehofski LJ; Honoré B; Vorum H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28452939
[TBL] [Abstract][Full Text] [Related]
10. Does laser still have a role in the management of retinal vascular and neovascular diseases?
Shah AM; Bressler NM; Jampol LM
Am J Ophthalmol; 2011 Sep; 152(3):332-339.e1. PubMed ID: 21742309
[TBL] [Abstract][Full Text] [Related]
11. [Management of aflibercept in routine clinical practice].
Cabrera López F
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
[TBL] [Abstract][Full Text] [Related]
12. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
13. Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan.
Hashimoto Y; Okada A; Matsui H; Yasunaga H; Aihara M; Obata R
Jpn J Ophthalmol; 2023 Jan; 67(1):109-118. PubMed ID: 36508060
[TBL] [Abstract][Full Text] [Related]
14. Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents.
Terauchi G; Shinoda K; Sakai H; Kawashima M; Matsumoto CS; Mizota A; Miyake Y
BMC Ophthalmol; 2019 Jun; 19(1):129. PubMed ID: 31208350
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema.
Kelkar A; Webers C; Shetty R; Kelkar J; Labhsetwar N; Pandit A; Malode M; Tidke S
Indian J Ophthalmol; 2020 Oct; 68(10):2143-2147. PubMed ID: 32971626
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
17. Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?
Manousaridis K; Talks J
Br J Ophthalmol; 2012 Feb; 96(2):179-84. PubMed ID: 22250209
[TBL] [Abstract][Full Text] [Related]
18. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?
Lim LS; Cheung CMG; Mitchell P; Wong TY
Am J Ophthalmol; 2011 Sep; 152(3):329-331. PubMed ID: 21855670
[No Abstract] [Full Text] [Related]
19. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
20. Vascular endothelial growth factor a in intraocular vascular disease.
Miller JW; Le Couter J; Strauss EC; Ferrara N
Ophthalmology; 2013 Jan; 120(1):106-14. PubMed ID: 23031671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
